Overview

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Status:
Not yet recruiting

Trial end date:
2022-09-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in non-small cell lung cancer

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.